Do you want to read an article? Please log in or register.
Meeting the Challenge of Identifying New Treatments for Type 2-low Neutrophilic Asthma
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Treatment options in type-2 low asthma
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J.
Hinks TS, Levine SJ, Brusselle GG
doi: 10.1183/13993003.00528-2020.
New approaches for identifying and testing potential new anti-asthma agents
Expert Opin Drug Discov.
Licari A, Castagnoli R, Brambilla I, Marseglia A, Tosca MA, Marseglia GL, Ciprandi G
doi: 10.1080/17460441.2018.
RECOMMENDED
Asthma
Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function
Respir Med.
Mansur AH, Srivastava S, Sahal A
doi: 10.1016/j.rmed.2018.08.005.
COMMENTED
Asthma
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Heaney LG, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker SM, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Mansur AH, Fowler SJ, Niven RM, Howarth PH, Lordan JL, Menzies-Gow A, Harrison TW, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID, investigators for the MRC Refractory Asthma Stratification Programme.
doi: 10.1016/S2213-2600(20)30397-0.
RECOMMENDED
Asthma
Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet.
Peters MC, Wenzel SE
doi: 10.1016/S0140-6736(19)33005-3.
RECOMMENDED
AsthmaPulmonary Fibrosis
New treatments in respiratory medicine in 2018 : asthma, cystic fibrosis and nocturnal positive pressure (CPAP or NIV)
Rev Med Suisse.
Plojoux J, Charbonnier F, Janssens JP
IgE sensitisation to food allergens and airborne allergens in relation to biomarkers of type 2 inflammation in asthma
Clin Exp Allergy.
Patelis A, Alving K, Middelveld R, James A, Ono J, Ohta S, Izuhara K, Borres MP, Forsberg B, Janson C, Malinovschi A
doi: 10.1111/cea.13165.
RECOMMENDED
Asthma
Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type-2 Inflammation
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
Kolmert J, Gómez C, Balgoma D, Sjödin M, Bood J, Konradsen JR, Ericsson M, Thörngren JO, James A, Mikus M, Sousa AR, Riley JH, Bates S, Bakke PS, Pandis I, Caruso M, Chanez P, Fowler SJ, Geiser T, Howarth P, Horváth I, Krug N, Montuschi P, Sanak M, Behndig A, Shaw DE, Knowles RG, Holweg CTJ, Wheelock ÅM, Dahlén B, Nordlund B, Alving K, Hedlin G, Chung KF, Adcock IM, Sterk PJ, Djukanovic R, Dahlén SE, Wheelock CE, U-BIOPRED Study Group
doi: 10.1164/rccm.201909-1869OC.
Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines
Horak F, Doberer D, Eber E, Horak E, Pohl W, Riedler J, Szépfalusi Z, Wantke F, Zacharasiewicz A, Studnicka M